144 related articles for article (PubMed ID: 3555385)
21. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC
Br J Psychiatry; 1985 May; 146():469-74. PubMed ID: 3893599
[TBL] [Abstract][Full Text] [Related]
22. Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
Steiner S; Nagy C
Int Pharmacopsychiatry; 1981; 16(3):184-92. PubMed ID: 7319750
[TBL] [Abstract][Full Text] [Related]
23. Fluphenazine decanoate and tardive dyskinesia: a possible association.
Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
[TBL] [Abstract][Full Text] [Related]
24. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
[TBL] [Abstract][Full Text] [Related]
25. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
26. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
McCreadie R; Mackie M; Morrison D; Kidd J
Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
[TBL] [Abstract][Full Text] [Related]
27. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Landmark J; Merskey H; Cernovsky ZZ
Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
[TBL] [Abstract][Full Text] [Related]
28. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
29. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
30. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
Schooler NR; Levine J; Severe JB; Brauzer B; DiMascio A; Klerman GL; Tuason VB
Arch Gen Psychiatry; 1980 Jan; 37(1):16-24. PubMed ID: 7352836
[TBL] [Abstract][Full Text] [Related]
31. Tardive dystonia. The benefits of time.
Cooper SJ; Doherty MM; King DJ
Br J Psychiatry; 1989 Jul; 155():113-5. PubMed ID: 2691000
[TBL] [Abstract][Full Text] [Related]
32. Acute dystonia during fixed-dose neuroleptic treatment.
Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
[TBL] [Abstract][Full Text] [Related]
33. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
34. Suicide associated with akathisia and depot fluphenazine treatment.
Shear MK; Frances A; Weiden P
J Clin Psychopharmacol; 1983 Aug; 3(4):235-6. PubMed ID: 6886035
[No Abstract] [Full Text] [Related]
35. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG
Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099
[TBL] [Abstract][Full Text] [Related]
36. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
37. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
[TBL] [Abstract][Full Text] [Related]
38. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.
Rifkin A; Quitkin F; Rabiner CJ; Klein DF
Arch Gen Psychiatry; 1977 Jan; 34(1):43-7. PubMed ID: 189724
[TBL] [Abstract][Full Text] [Related]
39. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
40. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
